Economic Analysis of Alliance A041202 CLL Study

Prospective Economic Analysis: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab Versus Ibrutinib + Rituximab vs Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

The planned analysis is a prospective cost-effectiveness (cost-utility) analysis from the perspective of the Canadian public healthcare system, examining the costs and outcomes (quality-adjusted life years gained) of ibrutinib-based therapy compared to a standard therapy (bendamutine-rituximab). Collection and management of the data required for the economic analyses (including resource utilization and outcomes) will be fully integrated into the clinical data. Health state utilities will be derived directly from the study population.

Economic Analysis of Alliance A041202 CLL Study

Recruitment

Summary

Participation Requirements

Description

Tracking Information